12:00 AM
 | 
May 07, 2012
 |  BC Week In Review  |  Company News  |  Deals

Kadimastem, Merck KGaA deal

Merck's Merck Serono division partnered with Kadimastem to use the Israeli company's drug-screening technology to discover oral therapies for multiple sclerosis (MS)....

Read the full 88 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$30 USD
More Info >